HTB May/June 2023 now online

1 June 2023. Related: News.

The article quotes this as being an average of 17 years (without noting the irony that this time is quoted from a 2011 paper published 12 years ago)  and uses examples from cardiovascular care and COVID, noting that only 1 in 5 evidence-based interventions make it to routine clinical practice. [2, 3]

And although the review positively references HIV research, it would be interesting to know where HIV compares to this average.

The hopefully faster timeline for advances in HIV to become clinical practice would likely be a marker of four factors.

1. Continued research in to HIV treatment; with public funded research such as the UK MRC, French ANRS, European NEAT and US ACTG networks including implementation studies.
2. A high awareness of results presented at medical conference before peer-review publication.
3. Access to regularly updated national and international guidelines (that also allow evidence from conference presentations).
4. Incorporation of implementation research by international health organisations and funders, including  WHO, IAS, PEPFAR etc – sometimes called operations or operational research. [4]

This extended timeline has also been often highlighted as a problem for data on people living with HIV who are routinely excluded from phase 3 regulatory studies or underrepresented in them including by age, ethnicity, gender and sex.

A plenary talk on ART-associated weight gain, given by Andrew Carr at the recent BHIVA conference, included a slide showing a delay of from 2 to 18 years in the time taken to attribute drug toxicity after drug approval. This talk is also reported in detail in this issue of HTB together with ssummaries of other signposted presentations. [5, 6, 7]

We conclude our reports from CROI 2023 noting that plenary talks are now available as open access. These excellent presentations by leading researchers are often underreported in community reports, and yet, similar to talks at the pre-conference investigator workshops summarise state-of-the-art research.

The talk on the HIV reservoir and cure-related research, by Janet Siliciano, included the recent awareness that long-term viral suppression on ART rather than steadily reducing the viral reservoir, actually leads to a slight increase. [8]

The increase however is driven by the clonal expansion of latently infected cells that are transcriptional deficient, and concludes that rather than indiscriminately targeting the entire viral reservoir, future cure-related studies could instead only selectively target cells that actively contribute to viral rebound when ART is stopped.

In a small way, compressing the timeline between integrating clinical advances into practice has always been an i-Base goal, including for HTB and it is sobering to note that the field of implementational science has developed during the 22 years that we have been publishing and reporting – especially during the last 16 or so years. [9, 10, 11, 12]

Happy reading.

References